Calcium Crystals Break Down Alzheimer's Brain Plaques in Lab Study
- Authors
- Nodoka Iwaya, Akikazu Sakudo, Takuya Kanda, Koichi Furusaki, Rumiko Onishi, Takashi Onodera, Yasuhiro Yoshikawa
- Journal
- International Journal of Molecular Sciences
- Year
- 2024
- DOI
- 10.3390/ijms252312761
- Study Type
- Cell Culture
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- Japan
- Health Condition
- Alzheimer's Disease
- Body System
- Nervous System
TL;DR
A natural compound called CAC-717 can break down harmful protein clumps associated with Alzheimer's disease and prevent them from forming.
Key Finding
CAC-717 broke apart amyloid-beta aggregates within seconds and prevented new aggregates from forming in laboratory conditions, with effects occurring in a dose-dependent manner.
Summary
This laboratory study tested whether a calcium bicarbonate crystal suspension called CAC-717 could break apart or prevent the buildup of amyloid-beta (Aβ), a protein clump found in the brains of Alzheimer's disease patients. Researchers created Aβ clumps in test tubes and exposed them to CAC-717, measuring whether the clumps broke down. The results showed that CAC-717 rapidly broke apart existing Aβ clumps and also prevented new ones from forming, suggesting it might be worth investigating further as a potential Alzheimer's treatment.
Practical Takeaway
While these results are promising, this was a laboratory study using test tubes, not human brains or living organisms, so it's too early to know if CAC-717 would work similarly in people with Alzheimer's disease. Much more research, including animal studies and eventually human trials, would be needed before any conclusions about its usefulness could be drawn. The study does suggest the compound deserves further investigation as a potential therapeutic approach.
Abstract
Amyloid-β (Aβ) aggregates accumulate in the brains of individuals with Alzheimer's disease and are thought to potentially act as prions, promoting further aggregation. Consequently, the biochemistry of Aβ has emerged as a promising target for Alzheimer's disease. CAC-717, a suspension of calcium bicarbonate mesoscopic structures derived from natural sources, has been shown to inactivate various pathogens, including prions. This study examined the effects of CAC-717 on both the formation and degradation/dissociation of Aβ aggregates using thioflavin T fluorescence and enzyme-linked immunosorbent assays. Aggregates of Aβ(1-42) peptide were generated by incubation at 37 °C for 24 h, and the effect of introducing CAC-717 on the aggregates was evaluated after further incubation at 25 °C for 30 min. Moreover, CAC-717 was also tested for its ability to inhibit the initial aggregation of Aβ. The results showed that CAC-717 significantly degraded and/or dissociated Aβ aggregates in a concentration-dependent manner. Specifically, CAC-717 treatment for 5 min disrupted Aβ aggregates to give Aβ monomer and oligomer concentrations as high as 130 nM compared to ~10 nM for the water control. In addition, CAC-717 degraded and/or dissociated aggregates within 10 s at 37 °C, and pre-treatment with CAC-717 significantly inhibited aggregation. These results suggest that CAC-717 not only degrades and/or dissociates Aβ aggregates but also inhibits their formation, highlighting its potential as a disinfectant for Alzheimer's disease.